Prices for GLP-1s are falling fast, forcing companies to adapt.

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive ...

Feb 12 (Reuters) - West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, banking on higher demand for diabetes and obesity treatments that use its medical equipment. The ...

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential ...

On a day when AbbVie revealed booming sales of Skyrizi and Rinvoq and another positive adjustment to its 2025 guidance, the company also is reportedly angling to bolster its long-term prospects by way ...

Sanofi has replaced its CEO Paul Hudson after a series of R&D setbacks at the French pharma, handing the reins to Merck KGaA leader Belén Garijo, M.D., Ph.D.

Opinion: Freedom-to-operate analysis must be understood as a continuous, integrated process that evolves alongside science, regulation, and commercial strategy.

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) today announced that it has entered into a definitive agreement to sell its Pharma Solutions business unit to French leader of plant-based ingredients ...

West Pharmaceutical Services has a business model centered around recurring consumption in the pharmaceutical and life sciences industries. The company has experienced consistent growth and has raised ...

This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023. ...

This story is part of Forbes’ coverage of India’s Richest 2025. See the full list here. Brothers Sudhir and Samir Mehta are riding the momentum of India’s ambition to become the world’s pharmacy. In ...

By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U.S. drug pricing are looking to craft their own ...